Ampersand Capital Partners acquires Nektar Therapeutics' PEG Reagent Manufacturing Business, Launching Gannet BioChem
Acquiring Company
Ampersand Capital Partners
Acquired Company
Gannet BioChem
HuntsvilleManufacturingBiotechnologyDescription
Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector, has completed the acquisition of Nektar Therapeutics' PEGylation reagent manufacturing business. The newly branded company, Gannet BioChem, will continue to operate out of its state-of-the-art facility in Huntsville, Alabama. Gannet BioChem is a proven leader in developing, scaling, and manufacturing PEG reagents, essential components in advanced biopharmaceutical and therapeutic products.
Quick answer
Ampersand Capital Partners is acquiring Gannet BioChem, announced December 2, 2024.
- How much did Ampersand Capital Partners pay for Gannet BioChem?
- The deal value was not disclosed.
- Where are Ampersand Capital Partners and Gannet BioChem based?
- Gannet BioChem is based in Huntsville, Alabama, United States.
Source: Fundz verified event record.
Other recent acquisitions in Manufacturing and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- H.B. Fuller Company signs agreements to acquire Medifill Ltd. and GEM S.r.l. to expand its Medical Adhesive Technologies business (December 2, 2024)
- Gemini Bioproducts, LLC Acquires Selected Fetal Bovine Serum (FBS) Product Rights and Inventory from Bio-Techne (November 25, 2024)
- Boston Scientific completes acquisition of Axonics, Inc. to expand into sacral neuromodulation (November 15, 2024)
- Huons Co., Ltd. acquires stake in PanGen to accelerate biopharmaceutical development (November 7, 2024)
- Canyon Labs completes acquisition of iuvo BioScience to strengthen end-to-end development solutions (January 7, 2025)
- Merck Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio (January 6, 2025)
Who to call at Ampersand Capital Partners, and when
When Ampersand Capital Partners changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Ampersand Capital Partners raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Ampersand Capital Partners, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Ampersand Capital Partners. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Ampersand Capital Partners makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Gannet BioChem?
Gannet BioChem was acquired by Ampersand Capital Partners. The deal was reported on December 2, 2024. Ampersand Capital Partners is privately held.
When did Ampersand Capital Partners acquire Gannet BioChem?
Ampersand Capital Partners's acquisition of Gannet BioChem was reported on December 2, 2024. Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector, has completed the acquisition of Nektar Therapeutics' PEGylation reagent manufacturing business. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Gannet BioChem do?
Gannet BioChem is a leading specialty CDMO with over 30 years of expertise in developing, scaling, and manufacturing polyethylene glycol (PEG) reagents—essential components in advanced biopharmaceutical and therapeutic products. Operating from a 124,000 sq. It is privately held, operating in Manufacturing, and is based in Huntsville.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.